ProShare Advisors’s Ventyx Biosciences VTYX Stock Holding History

ProShare Advisors’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,156	Closed	-$15.1K	–	2193
2025 Q1	$15.1K	Sell	13,156 -3,960	-23%	-$6.8K	﹤0.01%	2048
2024 Q4	$37.5K	Buy	17,116 +1,457	+9%	+$3.3K	﹤0.01%	2215
2024 Q3	$34.1K	Buy	15,659 +5,040	+47%	+$11.6K	﹤0.01%	2016
2024 Q2	$24.5K	Sell	10,619 -1,942	-15%	-$8.07K	﹤0.01%	1798
2024 Q1	$69.1K	Buy	12,561 +1,042	+9%	+$4.76K	﹤0.01%	1866
2023 Q4	$28.5K	Buy	11,519 +1,589	+16%	+$15.1K	﹤0.01%	1903
2023 Q3	$345K	Buy	9,930 +54	+0.5%	+$1.87K	﹤0.01%	1136
2023 Q2	$324K	Buy	9,876 +3,014	+44%	+$104K	﹤0.01%	1224
2023 Q1	$230K	Sell	6,862 -1,031	-13%	-$40.1K	﹤0.01%	1367
2022 Q4	$259K	Buy	+7,893	New	+$234K	﹤0.01%	1324

Other funds holding VTYX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ProShare Advisors's VTYX Position: Q2 2025 in Review

ProShare Advisors sold out of Ventyx Biosciences (VTYX) in Q2 2025, closing a stake of 13,156 shares — an estimated $15.1K sold.

ProShare Advisors first reported a position in VTYX in Q4 2022 and held it in 10 quarters. The position peaked at $345K in Q3 2023. 114 funds tracked by Wall St. Rank hold VTYX as of Q2 2025.

ProShare Advisors reported no remaining Ventyx Biosciences position as of Q2 2025 after selling out during the quarter.
ProShare Advisors sold 13,156 Ventyx Biosciences shares in Q2 2025, an estimated $15.1K.
ProShare Advisors first reported a position in Ventyx Biosciences in Q4 2022 and held it in 10 quarters.
ProShare Advisors's Ventyx Biosciences position peaked at $345K in Q3 2023.
114 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.